NeuroGen was established in 2024 when Mubadala Investment Company and C-Bridge Capital jointly carved out UCB’s mature product portfolios in China. Guided by their mission of "Innovating for Healthier, Better Lives," NeuroGen focuses on addressing high-unmet needs in neuroscience, with synergistic expansions into pain management, pediatrics, and allergy. By integrating best-in-class clinical solutions with affordable access, NeuroGen is building a scalable, growth-oriented biopharmaceutical platform dedicated to improving brain health and overall patient well-being.